Real-world variability in dabigatran levels in patients with atrial fibrillation: Comment

Journal of Thrombosis and Haemostasis

Volumn 13, Issue 6, 2015, Pages 1166-1168

  Douxfils, J ^a   Chatelain, B ^b   Dogne J M ^a   Mullier, F ^b  

^a University of Namur   (Belgium)

^b UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

DABIGATRAN; ANTITHROMBIN;

ATRIAL FIBRILLATION; BLOOD SAMPLING; DRUG ACCUMULATION; DRUG ADMINISTRATION; DRUG BLOOD LEVEL; DRUG MONITORING; FOLLOW UP; FUNCTION TEST KIT; HUMAN; LETTER; LIMIT OF QUANTITATION; PRIORITY JOURNAL; BLOOD; BLOOD CLOTTING; DRUG EFFECTS; FEMALE; MALE;

ANTITHROMBINS; ATRIAL FIBRILLATION; BLOOD COAGULATION; DABIGATRAN; FEMALE; HUMANS; MALE;

EID: 84930181252     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/jth.12880     Document Type: Letter

References (14)

1. Chan NC, Coppens M, Hirsh J, Ginsberg JS, Weitz JI, Vanassche T, Douketis JD, Schulman S, Eikelboom JW. Real-world variability in dabigatran levels in patients with atrial fibrillation. J Thromb Haemost 2015; 13: 353-9.
2. Liesenfeld KH, Lehr T, Dansirikul C, Reilly PA, Connolly SJ, Ezekowitz MD, Yusuf S, Wallentin L, Haertter S, Staab A. Population pharmacokinetic analysis of the oral thrombin inhibitor dabigatran etexilate in patients with non-valvular atrial fibrillation from the RE-LY trial. J Thromb Haemost 2011; 9: 2168-75.
3. Douxfils J, Lessire S, Dincq AS, Hjemdahl P, Ronquist-Nii Y, Pohanka A, Gourdin M, Chatelain B, Dogne JM, Mullier F. Estimation of dabigatran plasma concentrations in the perioperative setting. An ex vivo study using dedicated coagulation assays. Thromb Haemost 2015; 113: 862-9
4. European Medicines Agency. Pradaxa - summary of product characteristics. 24 Oct 2014. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000829/WC500041059.pdf. Accessed 06 February 2015.
5. Health Canada. Pradaxa - product monograph DIN 02312441. 07 Jan 2015. http://webprod5.hc-sc.gc.ca/dpd-bdpp/item-iteme.do?pm-mp=00028882. Accessed on 06 February 2015.
6. Food and Drug Administration. Pradaxa - full prescribing information. 15 Jan 2014. http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/022512s024lbl.pdf. Accessed on 06 Feb 2015.
7. Mismetti P, Laporte S. New oral antithrombotics: a need for laboratory monitoring. For. J Thromb Haemost 2010; 8: 621-6.
8. Reilly PA, Lehr T, Haertter S, Connolly SJ, Yusuf S, Eikelboom JW, Ezekowitz MD, Nehmiz G, Wang S, Wallentin L, Investigators R-L. The effect of dabigatran plasma concentrations and patient characteristics on the frequency of ischemic stroke and major bleeding in atrial fibrillation patients: the RE-LY Trial (Randomized Evaluation of Long-Term Anticoagulation Therapy). J Am Coll Cardiol 2014; 63: 321-8.
9. Douxfils J, Dogne JM, Mullier F, Chatelain B, Ronquist-Nii Y, Malmstrom RE, Hjemdahl P. Comparison of calibrated dilute thrombin time and aPTT tests with LC-MS/MS for the therapeutic monitoring of patients treated with dabigatran etexilate. Thromb Haemost 2013; 110: 543-9.
10. Douxfils J, Mullier F, Robert S, Chatelain C, Chatelain B, Dogne JM. Impact of dabigatran on a large panel of routine or specific coagulation assays. Laboratory recommendations for monitoring of dabigatran etexilate. Thromb Haemost 2012; 107: 985-97.
11. Antovic JP, Skeppholm M, Eintrei J, Boija EE, Soderblom L, Norberg EM, Onelov L, Ronquist-Nii Y, Pohanka A, Beck O, Hjemdahl P, Malmstrom RE. Evaluation of coagulation assays versus LC-MS/MS for determinations of dabigatran concentrations in plasma. Eur J Clin Pharmacol 2013; 69: 1875-81.
12. Skeppholm M, Hjemdahl P, Antovic JP, Muhrbeck J, Eintrei J, Ronquist-Nii Y, Pohanka A, Beck O, Malmstrom RE. On the monitoring of dabigatran treatment in "real life" patients with atrial fibrillation. Thromb Res 2014; 134: 783-9.
13. Hawes EM, Deal AM, Funk-Adcock D, Gosselin R, Jeanneret C, Cook AM, Taylor JM, Whinna HC, Winkler AM, Moll S. Performance of coagulation tests in patients on therapeutic doses of dabigatran: a cross-sectional pharmacodynamic study based on peak and trough plasma levels. J Thromb Haemost 2013; 11: 1493-502.
14. Rao RB. Regarding the effect of dabigatran plasma concentrations. J Am Coll Cardiol 2014; 63: 2885.